See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. For decades, advanced medical breakthroughs have followed a familiar ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Chimeric antigen receptor T-cell (CAR-T) therapy represents a major advance in hematologic oncology, demonstrating high ...
Under this expanded agreement, Cellares will provide proof-of-concept manufacturing for a second Bristol Myers Squibb CAR-T cell therapy The announcement comes weeks after Cellares first indicated ...
With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms
After recalibrating its production strategy in the late 2010s to better meet the realities of the CAR-T market, Gilead Sciences’ Kite Pharma is preparing to hit the ground running with the potential ...
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy that is manufactured in 48 hours using ...
GERMANTOWN, MD / ACCESS Newswire / July 16, 2026 / uBriGene Biosciences, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, today announced ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results